This inventor holds 3 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Celgene Corporation. Active years: 2018-2021.
Company Filing History:
Years Active: 2018-2021
Title: Innovations by Patrick Hagner in Cancer Treatment
Introduction
Patrick Hagner is an accomplished inventor based in Sparta, NJ (US). He has made significant contributions to the field of oncology, particularly in the treatment of various cancers. With a total of 3 patents to his name, Hagner's work focuses on improving drug efficacy and patient outcomes.
Latest Patents
Hagner's latest patents include innovative methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers. One of his notable patents outlines methods of using certain cereblon-associated proteins, such as Aiolos and Ikaros, as biomarkers for predicting and monitoring clinical sensitivity to specific compounds in patients with various cancers. Another patent details methods for predicting the responsiveness of DLBCL patients to treatments like lenalidomide, utilizing biomarkers that correlate with drug responsiveness.
Career Highlights
Patrick Hagner is currently employed at Celgene Corporation, where he continues to advance research in cancer therapies. His work has been instrumental in developing methods that enhance the effectiveness of treatments for patients suffering from complex diseases.
Collaborations
Hagner collaborates with talented professionals in his field, including Anita Gandhi and Matthew William Burnell Trotter. Their combined expertise contributes to the innovative research and development efforts at Celgene Corporation.
Conclusion
Patrick Hagner's contributions to cancer treatment through his patents and collaborative efforts highlight his commitment to improving patient care and advancing medical science. His work continues to pave the way for more effective therapies in oncology.